DOCSLIB.ORG

Draft National Chemicals Inventory As of Sep

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Draft National Chemicals Inventory As of Sep Draft National Chemicals Inventory as of Sep. 15 No. CAS Chemical Name (proposal) 1 50-00-0 Formaldehyde 2 50-03-3 Hydrocortisone acetate 3 50-14-6 Ergocalciferol 4 50-21-5 2-Hydroxypropanoic acid 5 50-24-8 Prednisolone 6 50-37-3 Lysergide 7 50-70-4 D-Glucitol 8 50-78-2 Aspirin 9 50-81-7 L-ascorbic acid 10 50-99-7 D-Glucose 11 51-03-6 5-Propan-1-yl-6-(2,5,8-trioxadodecan-1-yl)-1,3-benzodioxole 12 51-21-8 Fluorouracil 13 52-01-7 7alpha-(Acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone 14 52-28-8 Codeine phosphate 15 52-49-3 Trihexyphenidyl hydrochloride 16 52-76-6 Lynestrenol 17 52-89-1 Cysteine hydrochloride 18 52-90-4 L-cysteine 19 53-36-1 Methylprednisolone 21-acetate 20 53-86-1 Indometacin 21 54-05-7 Chloroquine 22 54-21-7 Sodium salicylate 23 54-31-9 Furosemide 24 54-64-8 Sodium ethanide[2-(sulfide-kappaS)benzoato-kappaO]mercurate(1-) 25 55-63-0 Nitroglycerin 26 56-04-2 Methylthiouracil 27 56-23-5 Tetrachloromethane 28 56-40-6 Glycine 29 56-41-7 L-alanine 30 56-45-1 L-Serine 31 56-75-7 Chloramphenicol 32 56-81-5 Glycerol 33 56-84-8 L-Aspartic acid 34 56-86-0 Glutamic acid 35 56-89-3 Cystine 36 57-03-4 1,2,3-Propanetriol, 1-(dihydrogen phosphate) 37 57-09-0 Cetrimonium bromide 38 57-10-3 Palmitic acid 39 57-11-4 Stearic acid 40 57-13-6 Urea 41 57-15-8 Chlorbutanol 42 57-24-9 Strychnine 43 57-48-7 D-Fructose 44 57-50-1 Sucrose 45 57-55-6 Propane-1,2-diol 46 58-08-2 1,3,7-Trimethyl-1H-purine-2,6(3H,7H)-dione 47 58-22-0 Testosterone 48 58-27-5 Menadione 49 58-56-0 3-Hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridin-1-ium chloride 50 58-61-7 Adenosine 1/67 Draft National Chemicals Inventory as of Sep. 15 No. CAS Chemical Name (proposal) 51 58-71-9 Cefalotin sodium 52 58-73-1 Diphenhydramine 53 58-85-5 Biotin 54 58-93-5 Hydrochlorothiazide 55 58-95-7 alpha-tocopheryl acetate 56 59-02-9 alpha-tocopherol 57 59-05-2 Methotrexate 58 59-26-7 Nikethamide 59 59-30-3 Folic acid 60 59-43-8 Thiamine 61 59-47-2 Mephenesin 62 59-50-7 4-Chloro-3-methylphenol 63 59-51-8 DL-Methionine 64 59-92-7 (S)-2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid 65 60-00-4 Ethylenediaminetetraacetic acid 66 60-10-6 1,5-diphenyl-3-thiocarbazone 67 60-12-8 .beta.-Phenylethylalcohol 68 60-18-4 Tyrosine 69 60-24-2 Ethanol, 2-mercapto- 70 60-29-7 Ethane, 1,1'-oxybis 71 60-32-2 Aminocaproic acid 72 60-33-3 Linoleic acid 73 60-35-5 Acetamide 74 61-68-7 Mefenamic acid 75 61-73-4 3,7-Bis(N,N-dimethylamino)phenothiazin-5-ium chloride 76 61-76-7 Phenylephrine hydrochloride 77 61-90-5 L-leucine 78 62-49-7 Choline 79 62-53-3 Aniline 80 62-55-5 Thioacetamide 81 62-56-6 Thiourea 82 62-76-0 Disodium oxalate 83 63-42-3 Lactose 84 63-45-6 Primaquine bis(phosphate) 85 63-68-3 L-Methionine 86 63-74-1 4-Aminobenzenesulfonamide 87 63-91-2 L-Phenylalanine 88 64-02-8 Tetrasodium 2,2',2'',2'''-(ethylenedinitrilo)tetraacetate 89 64-17-5 Ethanol 90 64-18-6 Formic acid 91 64-19-7 Acetic acid 92 64-67-5 Diethyl sulfate (S)-N-(1,2,3,10-Tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7- 93 64-86-8 yl)acetamide 94 65-23-6 Pyridoxine 95 65-71-4 5-methyluracil 96 65-85-0 Benzoic acid 97 65-86-1 Orotic acid 98 66-71-7 1,10-phenanthroline 99 66-84-2 Glucosamine hydrochloride 2/67 Draft National Chemicals Inventory as of Sep. 15 No. CAS Chemical Name (proposal) 3-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methylthiazol- 100 67-03-8 3-ium chloride monohydrochloride 101 67-43-6 N-carboxymethyliminobis(ethylenenitrilo)tetra(acetic acid) 102 67-48-1 2-Hydroxy-N,N,N-trimethylethanaminium chloride 103 67-56-1 Methanol 104 67-63-0 Propan-2-ol 105 67-64-1 Acetone 106 67-66-3 Chloroform 107 67-68-5 Dimethyl sulfoxide 108 67-71-0 Dimethyl sulphone 109 67-97-0 Colecalciferol 110 68-04-2 Trisodium citrate 111 68-11-1 Acetic acid, mercapto- 112 68-12-2 N,N-Dimethylformamide 113 68-19-9 Cyanocobalamin Sodium [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4- 114 68-89-3 yl)methylamino]methanesulphonate 115 69-09-0 Chlorpromazine hydrochloride Sodium [2S-[2alpha,5alpha,6beta(S*)]]-6-(aminophenylacetamido)-3,3- 116 69-52-3 dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 117 69-65-8 D-Mannitol 118 69-72-7 Salicylic acid 119 69-78-3 3,3'-dithiobis[6-nitrobenzoic] acid 120 70-18-8 Glutathione 121 70-26-8 L-ornithine 122 70-34-8 1-fluoro-2,4-dinitrobenzene 123 70-54-2 DL-lysine 124 71-00-1 Histidine 125 71-23-8 1-Propanol 126 71-36-3 1-Butanol 127 71-43-2 Benzene 128 72-14-0 Sulfathiazole 129 72-17-3 Sodium 2-hydroxypropanoate 130 72-18-4 L-valine 131 72-19-5 L-threonine 132 73-22-3 L-Tryptophan 133 73-32-5 L-isoleucine 134 73-40-5 Guanine 135 74-79-3 Arginine 136 74-82-8 Methane 137 74-84-0 Ethane 138 74-85-1 Ethene 139 74-86-2 Ethyne 140 74-87-3 Methyl chloride 141 74-93-1 Methanethiol 142 74-98-6 Propane 143 75-01-4 Ethene, chloro- 144 75-05-8 Acetonitrile 145 75-07-0 Acetaldehyde 146 75-09-2 Dichloromethane 3/67 Draft National Chemicals Inventory as of Sep. 15 No. CAS Chemical Name (proposal) 147 75-10-5 Difluoromethane 148 75-12-7 Formamide 149 75-13-8 isocyanic acid 150 75-18-3 Dimethyl sulfide 151 75-20-7 Calcium acetylide 152 75-21-8 Oxirane 153 75-36-5 Acetyl chloride 154 75-45-6 Chloro(difluoro)methane 155 75-46-7 Trifluoromethane 156 75-52-5 Nitromethane 157 75-56-9 2-Methyloxirane 158 75-59-2 Tetramethylammonium hydroxide 159 75-65-0 2-Methylpropan-2-ol 160 75-73-0 Methane, tetrafluoro- 161 75-75-2 Methanesulphonic acid 162 75-78-5 Dichlorodimethylsilane 163 75-85-4 2-Butanol, 2-methyl- 164 76-03-9 Trichloroacetic acid 165 76-22-2 1,7,7-Trimethyl-bicyclo[2,2,1]heptanone-2 9-alpha-fluoro-11-beta,21-dihydroxy-16-alpha,17-alpha- 166 76-25-5 isopropylidenedioxypregna-1,4-diene-3,20-dione 167 76-37-9 2,2,3,3-Tetrafluoropropan-1-ol 168 76-59-5 Bromothymol blue 169 76-60-8 Bromocresol green 170 77-09-8 3,3-Bis(4-hydroxyphenyl)isobenzofuran-1(3H)-one 171 77-58-7 Stannane, dibutylbis[(1-oxododecyl)oxy]- 172 77-78-1 Dimethyl sulfate 173 77-86-1 1,3-Propanediol, 2-amino-2-(hydroxymethyl)- 174 77-90-7 Citric acid, tributyl ester, acetate 175 77-92-9 Citric acid 176 77-99-6 1,3-Propanediol, 2-ethyl-2-(hydroxymethyl)- 177 78-10-4 Tetraethyl orthosilicate 178 78-42-2 Phosphoric acid, tris(2-ethylhexyl) ester 179 78-59-1 1,5,5-Trimethylcyclohexen-3-one 180 78-63-7 Hexane, 2,5-dimethyl-2,5-bis(t-butylperoxy)- 181 78-67-1 alpha,alpha'-Azobis (isobutyronitrile) 182 78-70-6 1,6-Octadien-3-ol, 3,7-dimethyl- 183 78-78-4 Butane, 2-methyl- 184 78-83-1 2-Methyl-1-propanol 185 78-92-2 Butan-2-ol 186 78-93-3 Ethyl methyl ketone 187 79-01-6 1,1,2-Trichloroethene 188 79-06-1 Acrylamide 189 79-09-4 Propionic acid 190 79-10-7 Acrylic acid 191 79-14-1 Glycollic acid 192 79-19-6 Thiosemicarbazide 193 79-20-9 Methyl acetate 194 79-24-3 Nitroethane 195 79-33-4 (S)-2-Hydroxypropanoic acid 4/67 Draft National Chemicals Inventory as of Sep. 15 No. CAS Chemical Name (proposal) 196 79-34-5 Ethane, 1,1,2,2-tetrachloro- 197 79-41-4 Methacrylic acid 198 79-43-6 Dichloroacetic acid 199 79-81-2 Retinyl palmitate 200 80-05-7 4,4'-Propane-2,2-diyldiphenol 201 80-09-1 4,4'-Sulfonyldiphenol 202 80-15-9 2-Hydroperoxy-2-phenylpropane 203 80-26-2 Terpinyl acetate 204 80-43-3 2-Phenyl-2-[(2-phenylpropan-2-yl)peroxy]propane 205 80-54-6 Propionaldehyde, 2-(4-tert-Butylbenzyl)- 206 80-62-6 Methyl methacrylate 207 80-73-9 1,3-Dimethyl-2-imidazolidinone 208 81-07-2 Saccharin 209 81-13-0 (R)-2,4-Dihydroxy-N-(3-hydroxypropan-1-yl)-3,3-dimethylbutanamide 210 81-25-4 Cholic acid 211 81-77-6 6,15-Dihydrodinaphtho[2,3-a:2,3-b]phenazine-5,9,14,18-tetrone 212 81-88-9 9-(2-carboxyphenyl)-3,6-bis(diethylamino)xanthylium chloride 213 83-73-8 Diiodohydroxyquinoline 214 83-88-5 7,8-Dimethyl-10-ribityl-isoalloxazine 215 84-51-5 Anthraquinone, 2-ethyl- 216 84-53-7 Uridine 3'-(dihydrogen phosphate) 217 84-58-2 4,5-dichloro-3,6-dioxocyclohexa-1,4-diene-1,2-dicarbonitrile 218 84-61-7 Dicyclohexan-1-yl phthalate 219 84-66-2 Diethyl phthalate 220 84-74-2 Dibutan-1-yl phthalate 221 85-44-9 Isobenzofuran-1,3-dione 222 85-68-7 Benzyl butan-1-yl phthalate 223 85-85-8 1-(2-pyridylazo)-2-naphthol 224 86-30-6 N,N-Diphenylnitrosoamine 225 86-87-3 1-naphthylacetic acid 226 87-02-5 7-Amino-4-hydroxynaphthalene-2-sulphonic acid 227 87-28-5 2-hydroxyethyl salicylate 228 87-33-2 Isosorbide dinitrate 229 87-51-4 Indol-3-ylacetic acid 230 87-61-6 1,2,3-Trichlorobenzene 231 87-62-7 Aniline, 2,6-dimethyl- 232 87-66-1 Pyrogallol Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, (2R,3R)-2,3- 233 87-67-2 dihydroxybutanedioate (1:1) 234 87-69-4 Butanedioic acid, 2,3-dihydroxy- [R-(R*,R*)]- 235 87-89-8 Myo-inositol 236 87-90-1 1,3,5-Trichloroisocyanuric acid 237 87-99-0 Xylitol 238 88-02-8 Toluene-2,4,6-triyltriamine 239 88-04-0 4-Chloro-3,5-xylenol 240 88-12-0 N-Vinyl-2-pyrrolidone 241 88-24-4 2,2'-Methylenebis(6-tert-butyl-4-ethylphenol) 242 88-58-4 2,5-Di-tert-butyl hydroquinone 243 88-74-4 2-Nitroaniline 244 88-89-1 Picric acid 5/67 Draft National Chemicals Inventory as of Sep.
Load more

Recommended publications
  • Complementary and Alternative Treatments for Alopecia: a Comprehensive Review
    Review Article Skin Appendage Disord 2019;5:72–89 Received: April 22, 2018 DOI: 10.1159/000492035 Accepted: July 10, 2018 Published online: August 21, 2018 Complementary and Alternative Treatments for Alopecia: A Comprehensive Review Anna-Marie Hosking Margit Juhasz Natasha Atanaskova Mesinkovska Department of Dermatology, University of California, Irvine, Irvine, CA, USA Keywords Introduction Alopecia · Complementary and alternative medicine · Efficacy According to the National Center for Complementary and Integrative Health (NCCIH), a branch of the Nation- al Institutes of Health (NIH; Bethesda, MD, USA), more Abstract than 30% of adults and 12% of children utilize treatments The treatment of alopecia is limited by a lack of therapies developed “outside of mainstream Western, or conven- that induce and sustain disease remission. Given the nega- tional, medicine,” with a total USD 30.2 billion out-of- tive psychosocial impact of hair loss, patients that do not pocket dollars spent annually [1]. In the treatment of alo- see significant hair restoration with conventional therapies pecia, there is an unmet need for therapies providing sat- often turn to complementary and alternative medicine isfying, long-term results. Patients often turn to (CAM). Although there are a variety of CAM treatment op- complementary and alternative medicine (CAM) in an tions on the market for alopecia, only a few are backed by attempt to find safe, natural, and efficacious therapies to multiple randomized controlled trials. Further, these mo- restore hair. Although CAMs boast hair-growing poten- dalities are not regulated by the Food and Drug Administra- tial, patients may be disappointed with results as there is tion and there is a lack of standardization of bioactive in- a lack of standardization of bioactive ingredients and lim- gredients in over-the-counter vitamins, herbs, and supple- ited scientific evidence.
    [Show full text]
  • WO 2014/167554 A2 16 October 2014 (16.10.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/167554 A2 16 October 2014 (16.10.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 47/10 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/IB20 14/060675 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 12 April 2014 (12.04.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: zw. 1103/DEL/2013 12 April 2013 (12.04.2013) IN (84) Designated States (unless otherwise indicated, for every (71) Applicant: VYOME BIOSCIENCES PVT. LTD. kind of regional protection available): ARIPO (BW, GH, [IN/IN]; 459 F.I.E, First Floor, Patparganj Industrial Area, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, New Delhi 110092 (IN).
    [Show full text]
  • Brochure-Product-Range.Pdf
    PRODUCT RANGE 2015 edition ANSI Standard 60 NSF® CERTIFIED HALAL M ISLAMIC FOOD AND NUTRITION ® COUNCIL OF AMERICA Rue Joseph Wauters, 144 ISO 9001:2008 (Quality) / OHSAS 18001:2007 (Health/ B-4480 Engis Safety) / ISO 14001:2004 (Environment) / ISO 22000:2005 www.globulebleu.com (Food Safety) / FSSC 22000:2013 (Food Safety). Tel. +32 (0) 4 273 93 58 Our food grade phosphates are allergen free, GMO free, Fax. +32 (0) 4 275 68 36 BSE/TSE free. www.prayon.com mail. [email protected] Design by www.prayon.com PRODUCT RANGE | 11 TABLE OF CONTENTS HORTICULTURE APPLICATIONS HORTIPRAY® RANGE FOR HORTICULTURE* FOOD AND INDUSTRIAL APPLICATIONS PRODUCT NAME Bulk density P O pH N-NH Made 2 5 4 MONOAMMONIUM PHOSPHATE - NH4H2PO4 in 3 3 % 1% % Sodium orthophosphates ................................................................................... 03 g/cm lbs/ft indicative indicative indicative Water-soluble fertilisers. Sodium pyrophosphates .................................................................................... 04 HORTIPRAY® MAP Horticultural Grade 0.9 56 61 4.5 12 Sodium tripolyphosphates ................................................................................. 05 HORTIPRAY® MAP 12.60 Horticultural Grade 0.9 56 60 5 12.1 Water-soluble fertilisers; Sodium polyphosphates ..................................................................................... 06 HORTIPRAY® MAP anticalc Horticultural Grade 0.9 56 61 4.5 12 preventive action against clogging. Potassium orthophosphates .............................................................................
    [Show full text]
  • Ionic Liquid + Biomolecule
    Sónia Isabel Pereira Branco Licenciatura em Ciências da Engenharia Química e Bioquímica Aqueous Biphasic System based on Cholinium Ionic Liquids: Extraction of Biologically Active Phenolic Acids Dissertação para obtenção do Grau de Mestre em Engenharia Química e Bioquímica Orientador: Doutora Isabel Maria Delgado Jana Marrucho Ferreira, Investigadora Coordenadora, Laboratório de Termodinâmica Molecular, ITQB-UNL Presidente: Doutora Susana Filipe Barreiros Arguente: Doutor Alexandre Babo de Almeida Paiva Vogal: Doutora Isabel Maria Delgado Jana Marrucho Ferreira Setembro 2014 II UNIVERSIDADE NOVA DE LISBOA Faculdade de Ciências e Tecnologia Departamento de Química Aqueous Biphasic System based on Cholinium Ionic Liquids: Extraction of Biologically Active Phenolic Acids Sónia Isabel Pereira Branco Dissertação apresentada na Faculdade de Ciências e Tecnologia da Universidade Nova de Lisboa para obtenção do grau Mestre em Engenharia Química e Bioquímica Orientadores: Doutora Isabel Maria Delgado Jana Marrucho Ferreira 2014 III IV Aqueous Biphasic Systems based on Cholinium Ionic Liquids: Extraction of Biologically Active Phenolic Acids COPYRIGHT Sónia Isabel Pereira Branco Faculdade de Ciências e Tecnologia Universidade Nova de Lisboa A Faculdade de Ciências e Tecnologia e a Universidade Nova de Lisboa têm o direito, perpétuo e sem limites geográficos, de arquivar e publicar esta dissertação através de exemplares impressos reproduzidos em papel ou de forma digital, ou por qualquer outro meio conhecido ou que venha a ser inventado, e de a divulgar através de repositórios científicos e de admitir a sua cópia e distribuição com objectivos educacionais ou de investigação, não comerciais, desde que seja dado crédito ao autor e editor. V VI Agradecimentos Durante a realização desta tese, contei com o apoio de várias pessoas sem as quais não teria concluído esta etapa.
    [Show full text]
  • Drug Consumption in 2017 - 2020
    Page 1 Drug consumption in 2017 - 2020 2020 2019 2018 2017 DDD/ DDD/ DDD/ DDD/ 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital ATC code Subgroup or chemical substance day % day % day % day % A ALIMENTARY TRACT AND METABOLISM 322,79 3 312,53 4 303,08 4 298,95 4 A01 STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01A STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01AA Caries prophylactic agents 11,90 3 10,48 4 8,42 5 8,45 7 A01AA01 sodium fluoride 11,90 3 10,48 4 8,42 5 8,45 7 A01AA03 olaflur 0,00 - 0,00 - 0,00 - 0,00 - A01AB Antiinfectives for local oral treatment 2,36 8 2,31 7 2,31 7 2,02 7 A01AB03 chlorhexidine 2,02 6 2,10 7 2,09 7 1,78 7 A01AB11 various 0,33 21 0,21 0 0,22 0 0,24 0 A01AD Other agents for local oral treatment 0,02 0 0,03 0 0,04 0 - - A01AD02 benzydamine 0,02 0 0,03 0 0,04 0 - - A02 DRUGS FOR ACID RELATED DISORDERS 73,05 3 71,13 3 69,32 3 68,35 3 A02A ANTACIDS 2,23 1 2,22 1 2,20 1 2,30 1 A02AA Magnesium compounds 0,07 22 0,07 22 0,08 22 0,10 19 A02AA04 magnesium hydroxide 0,07 22 0,07 22 0,08 22 0,10 19 A02AD Combinations and complexes of aluminium, 2,17 0 2,15 0 2,12 0 2,20 0 calcium and magnesium compounds A02AD01 ordinary salt combinations 2,17 0 2,15 0 2,12 0 2,20 0 A02B DRUGS FOR PEPTIC ULCER AND 70,82 3 68,91 3 67,12 3 66,05 4 GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 0,17 7 0,74 4 1,10 4 1,11 5 A02BA02 ranitidine 0,00 1 0,63 3 0,99 3 0,99 4 A02BA03 famotidine 0,16 7 0,11 8 0,11 10 0,12 9 A02BB Prostaglandins 0,04 62
    [Show full text]
  • Nexobrid 2 G Powder and Gel for Gel
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT NexoBrid 2 g powder and gel for gel 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial contains 2 g of concentrate of proteolytic enzymes enriched in bromelain, corresponding to 0.09 g/g concentrate of proteolytic enzymes enriched in bromelain after mixing (or 2 g/22 g gel). The proteolytic enzymes are a mixture of enzymes from the stem of Ananas comosus (pineapple plant). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder and gel for gel. The powder is off-white to light tan. The gel is clear and colourless. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications NexoBrid is indicated for removal of eschar in adults with deep partial- and full-thickness thermal burns. 4.2 Posology and method of administration NexoBrid should only be applied by trained healthcare professionals in specialist burn centres. Posology 2 g NexoBrid powder in 20 g gel is applied to a burn wound area of 100 cm2. NexoBrid should not be applied to more than 15% Total Body Surface Area (TBSA) (see also section 4.4, Coagulopathy). NexoBrid should be left in contact with the burn for a duration of 4 hours. There is very limited information on the use of NexoBrid on areas where eschar remained after the first application.
    [Show full text]
  • IFAC Summary of Phosphate Citations the International Food Additives
    IFAC Summary of Phosphate Citations The International Food Additives Council (IFAC) is a global association representing manufacturers of food ingredients, including phosphates used as food additives. IFAC strives for the harmonization of food additive standards and specifications worldwide, and supports regulatory processes to identify, categorize and document the safety of food additives. Phosphorus is an essential element critical for several key biochemical processes in the body, including development of cell membranes, growth of bones and teeth, maintenance of acid-base balance, and cellular energetics. Phosphorus is naturally occurring in various types of foods, including meat, grains, and dairy. Additionally, inorganic phosphates can be added to foods to improve texture, flavor, shelf life, and other technological functions. Inorganic phosphates are salts or esters of phosphoric acid. Phosphoric acid is produced starting with naturally-occurring phosphate ore mined around the world. As phosphoric acid, it can be combined with other elements such as calcium, potassium, and sodium into "salts." Phosphate additives are contained in a large number of processed foods and beverages and help contribute to the vast food supply while also minimizing food waste. Following is a comprehensive list of phosphates that are approved for use in food. All of these phosphates have either been approved by the US Food and Drug Administration (FDA) as a direct food additive or reviewed by FDA and determined to be generally recognized as safe (GRAS). Also included are the CAS numbers, International Numbering System (INS) numbers, Food Chemicals Codex (FCC) references and Joint FAO/WHO Expert Committee on Food Additives (JECFA) evaluations, as available.
    [Show full text]
  • What's the Best Treatment for Cradle Cap?
    From the CLINIcAL InQUiRiES Family Physicians Inquiries Network Ryan C. Sheffield, MD, Paul Crawford, MD What’s the best treatment Eglin Air Force Base Family Medicine Residency, Eglin Air for cradle cap? Force Base, Fla Sarah Towner Wright, MLS University of North Carolina at Chapel Hill Evidence-based answer Ketoconazole (Nizoral) shampoo appears corticosteroids to severe cases because to be a safe and efficacious treatment of possible systemic absorption (SOR: C). for infants with cradle cap (strength of Overnight application of emollients followed recommendation [SOR]: C, consensus, by gentle brushing and washing with usual practice, opinion, disease-oriented baby shampoo helps to remove the scale evidence, and case series). Limit topical associated with cradle cap (SOR: C). ® Dowden Health Media Clinical commentary ICopyrightf parents can’t leave it be, recommend brush to loosen the scale. Although mineral oil andFor a brush personal to loosen scale use noonly evidence supports this, it seems safe Cradle cap is distressing to parents. They and is somewhat effective. want everyone else to see how gorgeous This review makes me feel more FAST TRACK their new baby is, and cradle cap can make comfortable with recommending ketocon- their beautiful little one look scruffy. My azole shampoo when mineral oil proves If parents need standard therapy has been to stress to the insufficient. For resistant cases, a cute hat to do something, parents that it isn’t a problem for the baby. can work wonders. If the parents still want to do something
    [Show full text]
  • Development of Granulation Tissue Mimetic Scaffolds for Skin Healing
    Western University Scholarship@Western Electronic Thesis and Dissertation Repository 10-4-2018 12:30 PM Development Of Granulation Tissue Mimetic Scaffolds For Skin Healing Adam Hopfgartner The University of Western Ontario Supervisor Hamilton, Douglas W. The University of Western Ontario Co-Supervisor Pickering, J. Geoffrey. The University of Western Ontario Graduate Program in Biomedical Engineering A thesis submitted in partial fulfillment of the equirr ements for the degree in Master of Engineering Science © Adam Hopfgartner 2018 Follow this and additional works at: https://ir.lib.uwo.ca/etd Part of the Biomaterials Commons, and the Molecular, Cellular, and Tissue Engineering Commons Recommended Citation Hopfgartner, Adam, "Development Of Granulation Tissue Mimetic Scaffolds For Skin Healing" (2018). Electronic Thesis and Dissertation Repository. 5767. https://ir.lib.uwo.ca/etd/5767 This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of Scholarship@Western. For more information, please contact [email protected]. Abstract Impaired skin healing is a significant and growing clinical concern, particularly in relation to diabetes, venous insufficiency and immobility. Previously, we developed electrospun scaffolds for the delivery of periostin (POSTN) and connective tissue growth factor 2 (CCN2), matricellular proteins involved in the proliferative phase of healing. This study aimed to design and validate a novel electrosprayed coaxial microsphere for the encapsulation of fibroblast growth factor 9 (FGF9), as a component of the POSTN/CCN2 scaffold, to promote angiogenic stability during wound healing. For the first time, we observed a pro-proliferative effect of FGF9 on human dermal fibroblasts (HDF) in vitro, indicating a potential cellular mechanism of action during wound healing.
    [Show full text]
  • Dietary Supplements Compendium Volume 1
    2015 Dietary Supplements Compendium DSC Volume 1 General Notices and Requirements USP–NF General Chapters USP–NF Dietary Supplement Monographs USP–NF Excipient Monographs FCC General Provisions FCC Monographs FCC Identity Standards FCC Appendices Reagents, Indicators, and Solutions Reference Tables DSC217M_DSCVol1_Title_2015-01_V3.indd 1 2/2/15 12:18 PM 2 Notice and Warning Concerning U.S. Patent or Trademark Rights The inclusion in the USP Dietary Supplements Compendium of a monograph on any dietary supplement in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to exercise, any right or privilege protected by such patent or trademark. All such rights and privileges are vested in the patent or trademark owner, and no other person may exercise the same without express permission, authority, or license secured from such patent or trademark owner. Concerning Use of the USP Dietary Supplements Compendium Attention is called to the fact that USP Dietary Supplements Compendium text is fully copyrighted. Authors and others wishing to use portions of the text should request permission to do so from the Legal Department of the United States Pharmacopeial Convention. Copyright © 2015 The United States Pharmacopeial Convention ISBN: 978-1-936424-41-2 12601 Twinbrook Parkway, Rockville, MD 20852 All rights reserved. DSC Contents iii Contents USP Dietary Supplements Compendium Volume 1 Volume 2 Members . v. Preface . v Mission and Preface . 1 Dietary Supplements Admission Evaluations . 1. General Notices and Requirements . 9 USP Dietary Supplement Verification Program . .205 USP–NF General Chapters . 25 Dietary Supplements Regulatory USP–NF Dietary Supplement Monographs .
    [Show full text]
  • The Wound/Burn Guidelines –
    doi: 10.1111/1346-8138.13288 Journal of Dermatology 2016; : 1–22 GUIDELINE The wound/burn guidelines – 6: Guidelines for the management of burns Yuichiro YOSHINO,1 Mikio OHTSUKA,2 Masakazu KAWAGUCHI,3 Keisuke SAKAI,4 Akira HASHIMOTO,5 Masahiro HAYASHI,3 Naoki MADOKORO,6 Yoshihide ASANO,7 Masatoshi ABE,8 Takayuki ISHII,9 Taiki ISEI,10 Takaaki ITO,11 Yuji INOUE,12 Shinichi IMAFUKU,13 Ryokichi IRISAWA,14 Masaki OHTSUKA,15 Fumihide OGAWA,16 Takafumi KADONO,7 Tamihiro KAWAKAMI,17 Ryuichi KUKINO,18 Takeshi KONO,19 Masanari KODERA,20 Masakazu TAKAHARA,21 Miki TANIOKA,22 Takeshi NAKANISHI,23 Yasuhiro NAKAMURA,24 Minoru HASEGAWA,9 Manabu FUJIMOTO,9 Hiroshi FUJIWARA,25 Takeo MAEKAWA,26 Koma MATSUO,27 Osamu YAMASAKI,15 Andres LE PAVOUX,28 Takao TACHIBANA,29 Hironobu IHN,12 The Wound/Burn Guidelines Committee 1Department of Dermatology, Japanese Red Cross Kumamoto Hospital, Kumamoto, 2Department of Dermatology, Fukushima Medical University, Fukushima, 3Department of Dermatology, Yamagata University Faculty of Medicine, Yamagata, 4Intensive Care Unit, Kumamoto University Hospital, Kumamoto, 5Department of Dermatology, Tohoku University Graduate School of Medicine, Miyagi, 6Department of Dermatology, Mazda Hospital, Hiroshima, 7Department of Dermatology, Faculty of Medicine,University of Tokyo, Tokyo, 8Department of Dermatology, Gunma University Graduate School of Medicine, Gunma, 9Department of Dermatology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, 10Department of Dermatology, Kansai
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]